Why the study?
Will non-vitamin K antagonist oral anticoagulants become the new standard of care in anticoagulation therapy compared to warfarin?
Population
Patients requiring anticoagulation therapy, including those with atrial fibrillation or venous thromboembolism
Comparison
Non-vitamin K antagonist oral anticoagulants vs Warfarin and/or heparin
Design
Review
Authors
Loading...
Supports ongoing shift to NOACs in AF and VTE; leaves open whether they fully supplant warfarin as standard of care.
Will non-vitamin K antagonist oral anticoagulants become the new standard of care in anticoagulation therapy compared to warfarin?
This review discusses the ongoing paradigm shift from warfarin to non-vitamin K antagonist oral anticoagulants for stroke prophylaxis in atrial fibrillation and management of venous thromboembolism.
Ergene Oktay (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: